Mutagenesis reveals structure-activity parallels between human A(2A) adenosine receptors and biogenic amine G protein-coupled receptors

被引:58
作者
Jiang, QL [1 ]
Lee, BX [1 ]
Glashofer, M [1 ]
vanRhee, AM [1 ]
Jacobson, KA [1 ]
机构
[1] NIDDK,MOL RECOGNIT SECT,LBC,NIH,BETHESDA,MD 20892
关键词
D O I
10.1021/jm970084v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structure-affinity relationships for ligand binding at the human A(2A) adenosine receptor have been probed using site-directed mutagenesis in the transmembrane helical domains (TMs). The mutant receptors were expressed in COS-7 cells and characterized by binding of the radioligands [H-3]CGS21680; [H-3]NECA, and [H-3]XAC. Three residues, at positions essential for ligand binding in other G protein-coupled receptors, were individually mutated. The residue V(3.32) in the A(2A) receptor that is homologous to the essential aspartate residue of TM3 in the biogenic amine receptors, i.e., V84(3.32), may be substituted with L (present in the A(3) receptor) but not with D (in biogenic amine receptors) or A. H250(6.52), homologous to the critical N507 of rat m3 muscarinic acetylcholine receptors, may be substituted with other aromatic residues or with N but not with A (Kim et al. J. Biol. Chem. 1995, 270, 13987-13997). H278(7.43) homologous to the covalent ligand anchor site in rhodopsin, may not be substituted with either A, K, or N. Both V84L(3.32) and H250N(6.52) mutant receptors were highly variable in their effect on ligand competition depending on the structural class of the ligand. Adenosine-5'-uronamide derivatives were more potent at the H250N(6.52) mutant receptor than at wild type receptors. Xanthines tended to be close in potency (H250N(6.52)) or less potent (V84L(3.32)) than at wild type receptors. The affinity of CGS21680 increased as the pH was lowered to 5.5 in both the wild type and H250N(6.52) mutant receptors. Thus, protonation of H250(6.52) is not involved in this pH dependence. These data are consistent with a molecular model predicting the proximity of bound agonist ligands to TM3, TM5, TM6, and TM7.
引用
收藏
页码:2588 / 2595
页数:8
相关论文
共 51 条
[41]  
STRADER CD, 1989, J BIOL CHEM, V264, P16470
[42]  
TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373
[43]  
TUCKER AL, 1994, J BIOL CHEM, V269, P27900
[44]  
Van Rhee A M, 1995, Drug Des Discov, V13, P133
[45]   RELATIVE BINDING ORIENTATIONS OF ADENOSINE-A(1) RECEPTOR LIGANDS - A TEST-CASE FOR DISTRIBUTED MULTIPOLE ANALYSIS IN MEDICINAL CHEMISTRY [J].
VANDERWENDEN, EM ;
PRICE, SL ;
APAYA, RP ;
IJZERMAN, AP ;
SOUDIJN, W .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1995, 9 (01) :44-54
[46]  
vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO
[47]  
2-S
[48]   Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists [J].
vanRhee, AM ;
Siddiqi, SM ;
Melman, N ;
Shi, D ;
Padgett, WL ;
Daly, JW ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (02) :398-406
[49]   Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: Selectivity for A(3) receptors [J].
vanRhee, AM ;
Jiang, JL ;
Melman, N ;
Olah, ME ;
Stiles, GL ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2980-2989
[50]  
WANG CD, 1993, MOL PHARMACOL, V43, P931